{"id":"https://openalex.org/W4389239705","doi":"https://doi.org/10.1158/1535-7163.targ-23-b124","title":"Abstract B124: MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression","display_name":"Abstract B124: MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression","publication_year":2023,"publication_date":"2023-12-01","ids":{"openalex":"https://openalex.org/W4389239705","doi":"https://doi.org/10.1158/1535-7163.targ-23-b124"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-23-b124","doi":"https://doi.org/10.1158/1535-7163.targ-23-b124","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.targ-23-b124","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003058857","display_name":"William C. Comb","orcid":"https://orcid.org/0009-0008-2934-4305","observed_orcids":["https://orcid.org/0009-0008-2934-4305"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William C Comb","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010241998","display_name":"Deepak Kanojia","orcid":"https://orcid.org/0000-0003-4295-4972","observed_orcids":["https://orcid.org/0000-0003-4295-4972"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deepak Kanojia","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063858270","display_name":"Federico Colombo","orcid":"https://orcid.org/0000-0003-4480-3481","observed_orcids":["https://orcid.org/0000-0003-4480-3481"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Federico Colombo","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075560322","display_name":"Vijay Ramesh","orcid":"https://orcid.org/0009-0009-8190-2965","observed_orcids":["https://orcid.org/0009-0009-8190-2965"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vijay Ramesh","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002466763","display_name":"Nimish Gera","orcid":"https://orcid.org/0000-0003-2453-9468","observed_orcids":["https://orcid.org/0000-0003-2453-9468"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nimish Gera","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thomas Chittenden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Chittenden","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083047242","display_name":"Brian P. Fiske","orcid":"https://orcid.org/0000-0001-5891-4268","observed_orcids":["https://orcid.org/0000-0001-5891-4268"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Fiske","raw_affiliation_strings":["1Mythic Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mythic Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4405267374"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267374"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"12_Supplement","first_page":"B124","last_page":"B124"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.5342000126838684,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.5342000126838684,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.3402999937534332,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.0414000004529953,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9210000038146973},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.8809999823570251},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9929999709129333},{"id":"https://openalex.org/keywords/antibody-internalization","display_name":"antibody internalization","score":0.7730000019073486},{"id":"https://openalex.org/keywords/maytansinoids","display_name":"maytansinoids","score":0.6850000023841858},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8600000143051147},{"id":"https://openalex.org/keywords/nci-h1975","display_name":"NCI-H1975","score":0.9929999709129333}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6594250798225403},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.5657549500465393},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5073158144950867},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4916437268257141},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.47799673676490784},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4560756981372833},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4440310001373291},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.43510720133781433},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4118845462799072},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3872980773448944},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38541465997695923},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3103615641593933},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.25978565216064453},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10725268721580505},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-23-b124","doi":"https://doi.org/10.1158/1535-7163.targ-23-b124","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.targ-23-b124","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393090518","https://openalex.org/W4409690019","https://openalex.org/W4362542942","https://openalex.org/W4396561073","https://openalex.org/W4415940675","https://openalex.org/W4379281016","https://openalex.org/W4410803169","https://openalex.org/W4400108695","https://openalex.org/W4393100568","https://openalex.org/W2503715999"],"abstract_inverted_index":{"Abstract":[0],"cMET":[1,14,28,49,79,86,123,182,196,310,344,407],"overexpression":[2],"occurs":[3],"in":[4,38,93,108,115,178,191,247,319,330,340],"non-small":[5],"cell":[6,106],"lung":[7],"cancer":[8,105],"(NSCLC)":[9],"and":[10,97,164,176,199,231,271,312,322,327,339,421],"antibody-drug":[11],"conjugates":[12],"targeting":[13],"(cMET-ADCs)":[15],"have":[16,31],"been":[17],"developed":[18],"to":[19,65,128,149,162,185,202,208,223,288],"treat":[20],"cMET+":[21,94,104,320,364],"NSCLC":[22,42,116,301,365,400],"tumors":[23,45,76],"irrespective":[24],"of":[25,41,71,88,103,142,172,234,280,300,352,363,399,406,412],"dependency":[26],"on":[27,418],"signaling.":[29],"cMET-ADCs":[30],"shown":[32],"promising":[33],"clinical":[34,144,282],"activity,":[35],"but":[36,225],"largely":[37],"a":[39,68,101,135,143,272,281,289,298,331,355,360,389,397],"subset":[40],"patients":[43,72],"whose":[44,75],"express":[46,77],"the":[47,57,129,155,169,186,212,241,250,256,268,350,413],"highest":[48],"levels.":[50,80],"MYTX-011,":[51,224],"an":[52],"investigational,":[53],"pH-sensitive":[54,85],"ADC":[55,133,137,147,252,270,275,286,392],"incorporating":[56],"clinically":[58],"validated":[59],"vcMMAE":[60],"linker-payload,":[61],"was":[62,238,253,263,294,316],"specifically":[63],"designed":[64],"potentially":[66],"benefit":[67],"broader":[69,361],"population":[70],"including":[73],"those":[74],"lower":[78],"We\u2019ve":[81],"previously":[82],"demonstrated":[83],"that":[84,154,204,219],"binding":[87],"MYTX-011":[89,110,156,190,237,262,292,315,353,387],"drives":[90],"higher":[91],"internalization":[92],"tumor":[95],"cells,":[96],"greater":[98],"cytotoxicity":[99,193],"against":[100,240,297],"panel":[102,299],"lines":[107],"vitro.":[109],"also":[111],"shows":[112],"superior":[113],"efficacy":[114],"xenograft":[117,245,260,304],"models":[118,306,402],"with":[119,195,211,307,334,342,393,403],"high":[120],"or":[121,134,214],"moderate":[122,181,232,257],"expression":[124,197,408],"levels":[125,183,198,233,405],"when":[126],"compared":[127,184],"matched":[130,187,227],"non-pH-sensitive":[131],"Parent":[132],"Benchmark":[136,215,251,269],"generated":[138,210,276],"by":[139,277],"hinge":[140,278],"conjugation":[141,279],"stage":[145,283],"anti-cMET":[146,285],"antibody":[148,287],"vcMMAE.":[150],"Here":[151],"we":[152],"demonstrate":[153],"monoclonal":[157],"antibody,":[158],"which":[159],"is":[160,388],"engineered":[161],"selectively":[163],"rapidly":[165,174],"lose":[166],"affinity":[167],"at":[168],"acidic":[170],"pH":[171],"endolysosomes,":[173],"internalizes":[175],"accumulates":[177],"cells":[179,203,218],"expressing":[180],"parent":[188,213],"antibody.":[189],"vitro":[192],"correlated":[194],"conferred":[200],"sensitivity":[201],"were":[205,220],"otherwise":[206],"insensitive":[207],"ADCs":[209],"antibodies.":[216],"Importantly,":[217],"only":[221],"sensitive":[222],"not":[226],"controls,":[228],"expressed":[229],"low":[230,242],"cMET.":[235],"Furthermore,":[236],"active":[239,265,318],"cMET-expressing":[243,258],"NCI-H2122":[244],"model":[246,333],"vivo":[248],"whereas":[249],"inactive.":[254],"In":[255],"NCI-H1975":[259],"model,":[261],"more":[264],"than":[266,367],"both":[267],"second":[273],"benchmark":[274],"biparatopic":[284],"maytansinoid":[290],"linker/toxin.":[291],"activity":[293,395],"further":[295],"evaluated":[296],"patient":[302],"derived":[303],"(PDX)":[305],"relevant":[308],"histology,":[309],"expression,":[311],"genetic":[313],"profiles.":[314],"highly":[317,390],"squamous":[321],"adenocarcinoma":[323],"PDX,":[324,329],"EGFR":[325],"WT":[326],"mutant":[328],"PDX":[332,341],"MET":[335],"ex14":[336],"skipping":[337],"mutation,":[338],"heterogenous":[343],"expression.":[345],"Together,":[346],"these":[347],"findings":[348],"highlight":[349],"potential":[351],"as":[354],"therapeutic":[356],"candidate":[357],"for":[358],"treating":[359],"range":[362],"malignancies":[366],"other":[368],"cMET-ADCs.":[369],"Citation":[370],"Format:":[371],"William":[372],"C":[373],"Comb,":[374],"Deepak":[375],"Kanojia,":[376],"Federico":[377],"Colombo,":[378],"Vijay":[379],"Ramesh,":[380],"Nimish":[381],"Gera,":[382],"Thomas":[383],"Chittenden,":[384],"Brian":[385],"Fiske.":[386],"internalized":[391],"anti-tumor":[394],"across":[396],"spectrum":[398],"preclinical":[401],"various":[404],"[abstract].":[409],"In:":[410],"Proceedings":[411],"AACR-NCI-EORTC":[414],"Virtual":[415],"International":[416],"Conference":[417],"Molecular":[419],"Targets":[420],"Cancer":[422,433],"Therapeutics;":[423],"2023":[424],"Oct":[425],"11-15;":[426],"Boston,":[427],"MA.":[428],"Philadelphia":[429],"(PA):":[430],"AACR;":[431],"Mol":[432],"Ther":[434],"2023;22(12":[435],"Suppl):Abstract":[436],"nr":[437],"B124.":[438]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-12-02T00:00:00"}